{"id":11403522,"date":"2026-07-14T23:07:38","date_gmt":"2026-07-14T20:07:38","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&#038;p=11403522"},"modified":"2026-08-27T14:20:36","modified_gmt":"2026-08-27T11:20:36","slug":"adtralza-300-mg-tralokinumab","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/adtralza-300-mg-tralokinumab\/","title":{"rendered":"Adtralza 300 mg Tralokinumab Pre-filled Syringes"},"content":{"rendered":"<figure><img decoding=\"async\" src=\"https:\/\/nostylelike.net\/wp-content\/uploads\/2026\/07\/adtralza-300mg-main.webp\" alt=\"Adtralza 300 mg\" loading=\"lazy\"\/><\/figure>\n<p><strong>Adtralza 300 mg<\/strong> is available at No Style Like. Below you will find full details on its benefits, uses, dosage, and important precautions.<\/p>\n<div dir=\"ltr\" style=\"text-align: left;\">\n<h1 id=\"top\">Adtralza 300 mg (Tralokinumab) Pre-filled Syringes \u2014 Complete Guide for Atopic Dermatitis<\/h1>\n<div style=\"background: #f5f0fa; border-left: 4px solid #5b2d90; padding: 16px; border-radius: 8px;\">\n<p><strong>Quick Answer:<\/strong> Adtralza 300 mg is a biologic injection containing tralokinumab, used for moderate-to-severe atopic dermatitis (eczema) in adults and adolescents when topical treatments are not enough. It works by blocking interleukin-13 (IL-13), a key driver of eczema inflammation and itch. The dose is given as two 150 mg subcutaneous injections every two weeks after an initial loading dose, under medical supervision.<\/p>\n<\/div>\n<h2 id=\"key-facts\">Key Facts Table<\/h2>\n<table>\n<tbody>\n<tr>\n<th>Item<\/th>\n<th>Details<\/th>\n<\/tr>\n<tr>\n<td>Active ingredient<\/td>\n<td>Tralokinumab (fully human monoclonal antibody)<\/td>\n<\/tr>\n<tr>\n<td>Strength<\/td>\n<td>300 mg dose (2 \u00d7 150 mg pre-filled syringes)<\/td>\n<\/tr>\n<tr>\n<td>Drug class<\/td>\n<td>Biologic \u2014 IL-13 inhibitor<\/td>\n<\/tr>\n<tr>\n<td>Main use<\/td>\n<td>Moderate-to-severe atopic dermatitis<\/td>\n<\/tr>\n<tr>\n<td>Dosing<\/td>\n<td>600 mg loading dose, then 300 mg every 2 weeks<\/td>\n<\/tr>\n<tr>\n<td>Route<\/td>\n<td>Subcutaneous injection<\/td>\n<\/tr>\n<tr>\n<td>Storage<\/td>\n<td>Refrigerator 2\u20138\u00b0C, protect from light, never freeze<\/td>\n<\/tr>\n<tr>\n<td>Prescription status<\/td>\n<td>Prescription only \u2014 specialist supervision<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"short-desc\">Short Description<\/h2>\n<p>Adtralza (tralokinumab) is a targeted biologic therapy that neutralizes IL-13, reducing skin inflammation, itch, and lesion severity in atopic dermatitis that has not responded adequately to topical therapy. It can be used with or without topical corticosteroids.<\/p>\n<h2 id=\"toc\">Table of Contents<\/h2>\n<ul>\n<li><a href=\"#intro\">Introduction<\/a><\/li>\n<li><a href=\"#what-is\">What Is Adtralza?<\/a><\/li>\n<li><a href=\"#how-works\">How Does It Work?<\/a><\/li>\n<li><a href=\"#benefits\">Main Benefits<\/a><\/li>\n<li><a href=\"#use-cases\">Real Use Cases<\/a><\/li>\n<li><a href=\"#best-for\">Who Is It Best For?<\/a><\/li>\n<li><a href=\"#avoid\">Who Should Avoid It?<\/a><\/li>\n<li><a href=\"#how-to-use\">How to Use Correctly<\/a><\/li>\n<li><a href=\"#best-time\">Best Time to Use<\/a><\/li>\n<li><a href=\"#common-questions\">Common Questions Users Ask<\/a><\/li>\n<li><a href=\"#results-timeline\">Expected Results Timeline<\/a><\/li>\n<li><a href=\"#mistakes\">Common Mistakes<\/a><\/li>\n<li><a href=\"#myths\">Myths vs Facts<\/a><\/li>\n<li><a href=\"#interactions\">Drug Interactions<\/a><\/li>\n<li><a href=\"#contraindications\">Contraindications<\/a><\/li>\n<li><a href=\"#tests\">Required Tests<\/a><\/li>\n<li><a href=\"#nutrition\">What to Eat With It<\/a><\/li>\n<li><a href=\"#other-meds\">Effect on Other Medications<\/a><\/li>\n<li><a href=\"#see-doctor\">When To See a Doctor<\/a><\/li>\n<li><a href=\"#expert-tip\">NSL Expert Tip<\/a><\/li>\n<li><a href=\"#faq\">Conversational FAQ<\/a><\/li>\n<li><a href=\"#conclusion\">Conclusion<\/a><\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"intro\">Introduction<\/h2>\n<p>For adults living with widespread, relentlessly itchy eczema, creams alone often stop working. Adtralza belongs to the newer generation of biologic medicines designed for exactly this stage: instead of suppressing the whole immune system, it switches off one specific inflammatory signal \u2014 IL-13 \u2014 that sits at the center of atopic dermatitis. The result for many patients is calmer skin, less itching, and better sleep.<\/p>\n<hr \/>\n<h2 id=\"what-is\">What Is Adtralza?<\/h2>\n<p>Adtralza is a fully human monoclonal antibody (tralokinumab) developed by LEO Pharma. Each dose consists of two pre-filled 150 mg syringes injected under the skin. It is approved in Europe for moderate-to-severe atopic dermatitis in adults and adolescents from 12 years who are candidates for systemic therapy.<\/p>\n<hr \/>\n<h2 id=\"how-works\">How Does It Work?<\/h2>\n<p>Atopic dermatitis skin is flooded with interleukin-13, a signaling protein that drives inflammation, weakens the skin barrier, and triggers itch. Tralokinumab binds IL-13 directly and prevents it from docking onto its receptors. With the signal blocked, inflammation cools down, the barrier begins to repair, and the itch-scratch cycle weakens.<\/p>\n<hr \/>\n<h2 id=\"benefits\">Main Benefits<\/h2>\n<ul>\n<li>Targeted action on IL-13 without broad immunosuppression.<\/li>\n<li>Meaningful reduction in eczema extent and severity (EASI scores) in clinical trials.<\/li>\n<li>Noticeable itch relief, which improves sleep and daily life.<\/li>\n<li>Can be combined with topical corticosteroids when needed.<\/li>\n<li>Convenient every-two-weeks maintenance schedule; some well-controlled patients may move to every four weeks per their doctor.<\/li>\n<li>Suitable for long-term continuous use under specialist care.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"use-cases\">Real Use Cases<\/h2>\n<ul>\n<li>An adult whose eczema covers large body areas despite potent topical steroids and moisturizers.<\/li>\n<li>A patient cycling through repeated oral corticosteroid courses who needs a safer long-term option.<\/li>\n<li>An adolescent (12+) with severe eczema affecting school and sleep.<\/li>\n<li>A patient who could not tolerate ciclosporin or for whom it is contraindicated.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"best-for\">Who Is It Best For?<\/h2>\n<p>Adults and adolescents (12 years and older) with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatment, who are candidates for systemic therapy as judged by a dermatologist.<\/p>\n<hr \/>\n<h2 id=\"avoid\">Who Should Avoid It?<\/h2>\n<ul>\n<li>Anyone with known hypersensitivity to tralokinumab or its excipients.<\/li>\n<li>Patients with an active serious infection until it is treated.<\/li>\n<li>Patients with untreated parasitic (helminth) infections \u2014 these must be cleared first.<\/li>\n<li>Live vaccines should not be given during treatment; vaccination plans need review before starting.<\/li>\n<li>Pregnant or breastfeeding women only after a specialist risk\u2013benefit assessment.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"how-to-use\">How to Use Correctly<\/h2>\n<ol>\n<li>Initial loading dose: 600 mg (four 150 mg syringes) given at the start of treatment.<\/li>\n<li>Maintenance: 300 mg (two syringes) every two weeks, injected subcutaneously in the thigh or abdomen (avoid 5 cm around the navel).<\/li>\n<li>Take the syringes out of the refrigerator and let them reach room temperature before injecting, as instructed in the leaflet.<\/li>\n<li>Inject the two syringes at different sites; rotate sites at every session.<\/li>\n<li>Do not shake the syringes; do not use if the liquid is cloudy or discolored.<\/li>\n<li>Continue eye-care follow-up if you develop redness or irritation \u2014 conjunctivitis is a known side effect.<\/li>\n<\/ol>\n<hr \/>\n<h2 id=\"best-time\">Best Time to Use<\/h2>\n<p>Any time of day works \u2014 consistency of the two-week interval matters more than the hour. Setting a fixed calendar day (e.g., every other Saturday) prevents missed doses. If a dose is missed, inject as soon as possible, then return to the regular schedule.<\/p>\n<hr \/>\n<h2 id=\"common-questions\">Common Questions Users Ask<\/h2>\n<p><strong>Is Adtralza a steroid?<\/strong> No. It is a biologic antibody that blocks one inflammatory signal; it does not carry corticosteroid side effects.<\/p>\n<p><strong>Can I still use my creams?<\/strong> Yes \u2014 topical corticosteroids can be used alongside Adtralza when your doctor advises.<\/p>\n<p><strong>Does it cure eczema?<\/strong> No biologic cures atopic dermatitis; Adtralza controls it for as long as treatment continues.<\/p>\n<hr \/>\n<h2 id=\"results-timeline\">Expected Results Timeline<\/h2>\n<table>\n<tbody>\n<tr>\n<th>Period<\/th>\n<th>What to Expect<\/th>\n<\/tr>\n<tr>\n<td>2\u20134 weeks<\/td>\n<td>Early itch reduction in many patients.<\/td>\n<\/tr>\n<tr>\n<td>8\u201312 weeks<\/td>\n<td>Visible improvement in skin lesions; response formally assessed around week 16.<\/td>\n<\/tr>\n<tr>\n<td>16 weeks<\/td>\n<td>Decision point: your doctor evaluates whether to continue, adjust interval, or reconsider therapy.<\/td>\n<\/tr>\n<tr>\n<td>Beyond<\/td>\n<td>Continued or deepening control with ongoing treatment.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"mistakes\">Common Mistakes<\/h2>\n<ul>\n<li>Injecting cold syringes straight from the fridge \u2014 painful and unnecessary.<\/li>\n<li>Stopping treatment as soon as the skin clears, which usually brings the flare back.<\/li>\n<li>Skipping the loading dose or stretching intervals without medical approval.<\/li>\n<li>Ignoring persistent red or sticky eyes instead of reporting them.<\/li>\n<li>Receiving a live vaccine mid-treatment without telling the prescriber.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"myths\">Myths vs Facts<\/h2>\n<table>\n<tbody>\n<tr>\n<th>Myth<\/th>\n<th>Fact<\/th>\n<\/tr>\n<tr>\n<td>&#8220;Biologics destroy your immunity.&#8221;<\/td>\n<td>Adtralza blocks a single cytokine (IL-13); it is not broad immunosuppression, though infection vigilance is still required.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;If creams failed, nothing will work.&#8221;<\/td>\n<td>Systemic biologics act from inside the body and help many patients whom topicals could not control.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;You feel results from the first injection.&#8221;<\/td>\n<td>Meaningful improvement builds over weeks; the formal response check is around week 16.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"interactions\">Drug Interactions<\/h2>\n<ul>\n<li><strong>Live vaccines<\/strong> (e.g., MMR, yellow fever): avoid during treatment; complete them beforehand per your doctor.<\/li>\n<li><strong>Inactivated vaccines<\/strong> (e.g., influenza, COVID-19): generally acceptable \u2014 confirm timing with the prescriber.<\/li>\n<li>No significant cytochrome-based interactions are expected, but always disclose all medicines, including immunosuppressants, before starting.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"contraindications\">Contraindications<\/h2>\n<p>Hypersensitivity to tralokinumab or any excipient. Treatment should not start during an active serious infection or untreated helminth infection, and live vaccines are not to be administered concurrently.<\/p>\n<hr \/>\n<h2 id=\"tests\">Required Tests<\/h2>\n<ul>\n<li>Screening for active infections before starting, per specialist judgment.<\/li>\n<li>Review and completion of the vaccination schedule before the first dose.<\/li>\n<li>Parasite screening in patients from or traveling to endemic areas when indicated.<\/li>\n<li>Routine dermatology follow-up (EASI\/itch scoring) to document response by week 16.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"nutrition\">What to Eat With It<\/h2>\n<p>No food restrictions apply to Adtralza itself. Supporting skin health helps the treatment: adequate protein, omega-3 sources (fish, flaxseed), and good hydration. If you have confirmed food triggers identified with your doctor or allergist, keep avoiding them \u2014 but do not start elimination diets on your own, as unnecessary restriction harms more than it helps.<\/p>\n<hr \/>\n<h2 id=\"other-meds\">Effect on Other Medications<\/h2>\n<p>Tralokinumab does not meaningfully alter how the liver processes other drugs. The practical considerations are vaccine timing (above) and coordination when transitioning from other systemic eczema therapies (ciclosporin, methotrexate, oral steroids) \u2014 your dermatologist plans the overlap or washout. Do not layer systemic immunotherapies on your own.<\/p>\n<hr \/>\n<h2 id=\"see-doctor\">When To See a Doctor<\/h2>\n<ul>\n<li>Eye redness, itching, discharge, or vision changes.<\/li>\n<li>Signs of infection: fever, persistent cough, skin becoming hot, swollen, and painful.<\/li>\n<li>Any allergic reaction: facial swelling, breathing difficulty, widespread hives.<\/li>\n<li>No meaningful improvement by week 16.<\/li>\n<li>Before any planned vaccination, surgery, or pregnancy.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"expert-tip\">NSL Expert Tip<\/h2>\n<div style=\"background: #fdf2f7; border: 1px solid #d63384; padding: 14px; border-radius: 8px;\">\n<p><strong>Dr. Abdallah Fouad \u2014 Clinical Nutrition Specialist:<\/strong> Patients often judge a biologic in the first month and give up too early. With tralokinumab, the fair test is week 16 with consistent dosing and continued moisturizer routine. And never neglect eye symptoms \u2014 early treatment of conjunctivitis keeps therapy on track instead of interrupting it.<\/p>\n<\/div>\n<hr \/>\n<h2 id=\"faq\">Conversational FAQ<\/h2>\n<p><strong>How is Adtralza different from Dupixent?<\/strong><br \/>\nDupilumab blocks IL-4 and IL-13 signaling; tralokinumab targets IL-13 alone. Both are injectable biologics for atopic dermatitis \u2014 the choice is a specialist decision based on your profile.<\/p>\n<p><strong>Can the interval be extended?<\/strong><br \/>\nSome patients with clear or almost-clear skin at week 16 may move to 300 mg every four weeks \u2014 only by the prescriber&#8217;s decision.<\/p>\n<p><strong>Is it safe for teenagers?<\/strong><br \/>\nIt is approved from age 12 for moderate-to-severe atopic dermatitis under specialist care.<\/p>\n<p><strong>Do I stop my moisturizers?<\/strong><br \/>\nNo \u2014 daily emollients remain the foundation of eczema care alongside any biologic.<\/p>\n<p><strong>What if I get pregnant during treatment?<\/strong><br \/>\nInform your doctor immediately; continuing or pausing is an individualized specialist decision.<\/p>\n<hr \/>\n<h2 id=\"conclusion\">Conclusion<\/h2>\n<p>Adtralza 300 mg offers precise, steroid-free control of moderate-to-severe atopic dermatitis by neutralizing IL-13 at the source. With correct injection technique, a consistent two-week schedule, vaccine planning, and attention to eye symptoms, most suitable patients reach a level of skin control that topical therapy alone could not deliver. It is a specialist-supervised, prescription-only biologic from the first dose onward.<\/p>\n<div style=\"background: #f8f9fa; border: 1px solid #dee2e6; padding: 12px; border-radius: 8px; font-size: 0.9em;\">\n<p><strong>Medically reviewed by:<\/strong> Dr. Abdallah Fouad \u2014 Clinical Nutrition Specialist, 25+ years of clinical experience.<\/p>\n<p><strong>Medical Disclaimer:<\/strong> This content is educational and is not a substitute for professional medical advice. Adtralza is a prescription-only biologic requiring specialist supervision. Sources: European Medicines Agency (EMA) product information for Adtralza; National Eczema Association resources.<\/p>\n<\/div>\n<\/div>\n<h2>Related Products &#038; Useful Resources<\/h2>\n<p>You may also like related products such as <a href=\"https:\/\/nostylelike.net\/en\/product\/buy-panadol-cold-flu-24-caplets-fast-relief-for-cold-flu-symptoms\/\">Buy Panadol Cold &#038; Flu 24 Caplets \u2013<\/a> , <a href=\"https:\/\/nostylelike.net\/en\/product\/panadol-extra-24-tablets-fast-pain\/\">Panadol Extra 24 Tablets<\/a> from our store.<\/p>\n<p>For more trusted medical information, refer to <a href=\"https:\/\/www.drugs.com\/\" target=\"_blank\" rel=\"noopener nofollow\">Drugs.com<\/a>. Always consult your doctor or pharmacist before use.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adtralza 300 mg (tralokinumab) is a targeted IL-13 biologic for moderate-to-severe atopic dermatitis in adults and adolescents. Prescription only, specialist-supervised.<\/p>\n","protected":false},"featured_media":11403648,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[42048,41601],"product_tag":[],"class_list":["post-11403522","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory","product_cat-autoimmune-disease-treatments","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/comments?post=11403522"}],"version-history":[{"count":3,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403522\/revisions"}],"predecessor-version":[{"id":11405934,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403522\/revisions\/11405934"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media\/11403648"}],"wp:attachment":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media?parent=11403522"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_brand?post=11403522"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_cat?post=11403522"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_tag?post=11403522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}